全文获取类型
收费全文 | 2455篇 |
免费 | 226篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 78篇 |
妇产科学 | 17篇 |
基础医学 | 335篇 |
口腔科学 | 74篇 |
临床医学 | 268篇 |
内科学 | 608篇 |
皮肤病学 | 25篇 |
神经病学 | 200篇 |
特种医学 | 79篇 |
外国民族医学 | 1篇 |
外科学 | 262篇 |
综合类 | 8篇 |
一般理论 | 2篇 |
预防医学 | 154篇 |
眼科学 | 94篇 |
药学 | 275篇 |
肿瘤学 | 193篇 |
出版年
2023年 | 34篇 |
2022年 | 17篇 |
2021年 | 69篇 |
2020年 | 71篇 |
2019年 | 89篇 |
2018年 | 95篇 |
2017年 | 80篇 |
2016年 | 104篇 |
2015年 | 100篇 |
2014年 | 131篇 |
2013年 | 160篇 |
2012年 | 214篇 |
2011年 | 199篇 |
2010年 | 87篇 |
2009年 | 87篇 |
2008年 | 151篇 |
2007年 | 121篇 |
2006年 | 128篇 |
2005年 | 113篇 |
2004年 | 108篇 |
2003年 | 88篇 |
2002年 | 85篇 |
2001年 | 26篇 |
2000年 | 20篇 |
1999年 | 22篇 |
1998年 | 24篇 |
1997年 | 23篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 18篇 |
1993年 | 12篇 |
1992年 | 9篇 |
1991年 | 15篇 |
1990年 | 13篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 15篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1984年 | 8篇 |
1983年 | 15篇 |
1982年 | 4篇 |
1981年 | 7篇 |
1979年 | 15篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 7篇 |
1971年 | 4篇 |
1970年 | 6篇 |
1966年 | 4篇 |
排序方式: 共有2688条查询结果,搜索用时 15 毫秒
1.
2.
Wenjing Tao Miia Artama My von Euler-Chelpin Mark Hull Rickard Ljung Elsebeth Lynge Guðríður H. Ólafsdóttir Eero Pukkala Pål Romundstad Mats Talbäck Laufey Tryggvadottir Jesper Lagergren 《International journal of cancer. Journal international du cancer》2020,147(3):728-735
Obesity is a risk factor for colorectal cancer. Yet, some research indicates that weight-reducing bariatric surgery also increases colorectal cancer risk. Our study was undertaken because current evidence examining bariatric surgery and risk of colorectal cancer is limited and inconsistent. This population-based cohort study included adults with a documented obesity diagnosis in Denmark, Finland, Iceland, Norway or Sweden in 1980–2015. The incidence of colorectal cancer in participants with obesity who had and had not undergone bariatric surgery was compared to the incidence in the corresponding background population by calculating standardized incidence ratios (SIR) with 95% confidence intervals (CI). Additionally, operated and nonoperated participants with obesity were compared using multivariable Cox regression, providing hazard ratios (HR) with 95% CIs adjusted for confounders. Among 502,772 cohort participants with an obesity diagnosis, 49,931(9.9%) underwent bariatric surgery. The overall SIR of colon cancer was increased after bariatric surgery (SIR 1.56; 95% CI 1.28–1.88), with higher SIRs ≥10 years postsurgery. The overall HR of colon cancer in operated compared to nonoperated participants was 1.13 (95% CI 0.92–1.39) and 1.55 (95% CI 1.04–2.31) 10–14 years after bariatric surgery. Bariatric surgery did not significantly increase the risk of rectal cancer (SIR 1.14, 95% CI 0.83–1.52; HR 1.08, 95% CI 0.79–1.49), but the risk estimates increased with longer follow-up periods. Our study suggests that bariatric surgery is associated with an increased risk of colon cancer, while the support for an increased risk of rectal cancer was weaker. 相似文献
3.
4.
Erik L. Frandsen Jessica Otero Joe C. Rutledge Mariska S. Kemna Erin L. Albers Borah J. Hong Yuk M. Law Joshua M. Friedland‐Little 《Pediatric transplantation》2020,24(1)
Bortezomib is approved for the treatment of multiple myeloma but increasingly used in heart transplant (HTx) recipients with antibody‐mediated rejection (AMR). Severe pulmonary toxicity is a rare complication in multiple myeloma patients treated with bortezomib, but has not been described in a solid organ transplant recipient. A 20‐year‐old man 7 years post‐HTx presented with acute rejection with hemodynamic compromise. Endomyocardial biopsy showed mixed rejection (ISHLT grade 2R‐3R acute cellular rejection (ACR) and pAMR 1 (I+) with diffuse C4d staining). Two new high MFI circulating MHC class‐II donor‐specific antibodies (DSA) were detected. Treatment included corticosteroids, antithymocyte globulin, plasmapheresis, IVIG, rituximab, and bortezomib (1.3 mg/m2). Due to rebound in DSA, a second course of bortezomib was started. Thrombocytopenia and peripheral neuropathy prompted a 50% dose reduction during the 2nd course. Shortly after the 3rd reduced dose, the patient developed hypoxemic respiratory failure. Bronchoscopy revealed pulmonary hemorrhage with negative infectious studies. Chest CT showed bilateral parenchymal disease with bronchiectasis and alveolar bleeding. Despite treatment with high‐dose steroids, severe ARDS ensued with multisystem organ failure. The patient expired 23 days after the final dose of bortezomib. Post‐mortem lung histology revealed diffuse alveolar damage, pulmonary fibrosis, and hemorrhage. Cardiac histology showed resolving/residual ACR 1R and pAMR 1 (I+). While rare, bortezomib‐induced lung toxicity (BILT) can occur in HTx recipients and can carry a high risk of mortality. Drug reaction and immediate drug withdrawal should be considered in patients who develop respiratory symptoms, though optimal management of BILT is unclear. 相似文献
5.
Anca A. Arbune Jesper Jeppesen Isa Conradsen Philippe Ryvlin Sándor Beniczky 《Epilepsia》2020,61(Z1):S55-S60
This study aims at defining objective parameters reflecting the severity of peri-ictal autonomic changes and their relation to post-ictal generalized electroencephalography (EEG) suppression (PGES), with the view that such changes could be detected by wearable seizure detection systems and prove useful to assess the risk of sudden unexpected death in epilepsy (SUDEP). To this purpose, we assessed peri-ictal changes in heart rate variability (HRV) and correlated them with seizure duration, intensity of electromyography-based ictal muscle activity, and presence and duration of post-ictal generalized EEG suppression (PGES). We evaluated 75 motor seizures from 40 patients, including 61 generalized tonic-clonic seizures (GTCS) and 14 other major motor seizure types. For all major motor seizures, HRV measurements demonstrated a significantly decreased parasympathetic activity and increased sympathetic activity in the post-ictal period. The post-ictal increased sympathetic activity was significantly higher for GTCS as compared with non-GTCS. The degree of peri-ictal decreased parasympathetic activity and increased sympathetic activity was associated with longer PGES (>20 s), longer seizure duration, and greater intensity of ictal muscle activity. Mean post-ictal heart rate (HR) was an independent predictor of PGES duration, seizure duration, and intensity of ictal muscle contraction. Our results indicate that peri-ictal changes in HRV are potential biomarkers of major motor seizure severity. 相似文献
6.
7.
8.
Anders Elm Pedersen Esben Gjerløff Wedebye Schmidt Jesper Freddie Sørensen Carsten Faber Boye Schnack Nielsen Kim Holmstrøm Silje Haukali Omland Peter Tougaard Søren Skov Bo Bang 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(7):547-555
TL1A is a TNF‐like cytokine which has been shown to co‐stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF‐α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti‐TNF‐α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large‐scale studies are warranted to investigate TL1A as a biomarker. 相似文献
9.
10.
Rasmus Blechingberg Friis Niels Henrik Hjøllund Helle Pappot Gry Assam Taarnhøj Jesper Medom Vestergaard Halla Skuladottir 《Clinical lung cancer》2021,22(2):e169-e179
BackgroundPatient-reported outcome (PRO) measures have been increasingly implemented in routine care to aid in clinical decision-making. However, the prognostic value of PRO measures as a tool for decision making is not easily interpreted by clinicians. Our aims were to explore the prognostic value of PRO measures at disease progression and the changes in PRO measures between treatment start (baseline) and disease progression.Patients and MethodsSince 2014, patients with lung cancer have completed an electronic version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and LC-13 before every outpatient visit at the Department of Oncology, Hospital Unit West, Jutland, Denmark. The patients’ responses were used in routine care. Patients receiving palliative antineoplastic treatment were eligible for analysis if the questionnaire had been completed at the initiation of first-line treatment and at disease progression. The prognostic value of the scores was evaluated using a Cox proportional hazard model. A P value < .01 was considered statistically significant.ResultsA total of 94 screened patients were included. At disease progression, survival could be predicted from the absolute score of the global health scale, 3 functional scales (physical, role, emotional), and 7 symptom scales (fatigue, pain, dyspnea, hemoptysis, lung cancer dyspnea, chest pain). In addition, changes in hemoptysis, dysphagia, dyspnea, and chest pain predicted for survival at progression.ConclusionPRO measures used in routine care can provide clinicians with relevant prognostic information about patients with lung cancer at disease progression. These results show the potential value of PRO measures when used in clinical decision-making. 相似文献